Á lódáil...
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib
PURPOSE: We evaluated the safety and feasibility of anti-CD19 chimeric antigen receptor–modified T (CAR-T) cell therapy in patients with chronic lymphocytic leukemia (CLL) who had previously received ibrutinib. METHODS: Twenty-four patients with CLL received lymphodepleting chemotherapy and anti-CD1...
Na minha lista:
| Foilsithe in: | J Clin Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe: |
American Society of Clinical Oncology
2017
|
| Ábhair: | |
| Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5590803/ https://ncbi.nlm.nih.gov/pubmed/28715249 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.72.8519 |
| Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|